Design strategies of novel NNRTIs to overcome drug resistance.
about
Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.Synthesis and biological evaluation of 2-thioxopyrimidin-4(1H)-one derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.Design, synthesis, and biological evaluation of 1,3-diarylpropenones as dual inhibitors of HIV-1 reverse transcriptase.Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tractDrug discovery beyond the rule of 5 - Opportunities and challenges.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010)."Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.Conformational restriction: an effective tactic in 'follow-on'-based drug discovery.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach.Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors.Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.Pharmacophore Identification, Molecular Docking, Virtual Screening, and In Silico ADME Studies of Non-Nucleoside Reverse Transcriptase Inhibitors.Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2).Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase.Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928).Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents.Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitorsArylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism ApproachSynthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptaseDiscovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approachThermodynamic Profiling of Carbonic Anhydrase Inhibitors
P2860
Q28533728-0CDE6BF8-88B1-4739-A1A4-57F2E46F84B3Q34242282-DA40D7B2-6768-4CC5-9B70-E9959EB18548Q34685500-7FE42530-6C0C-4E7E-B8B2-56B57513D05DQ35172317-BBD37E8E-CDAF-4143-9FE7-649A9D8CF2F2Q36098779-015A409F-A684-473A-875D-FB98D788F0EDQ36203347-36D03543-3BB0-4779-8B19-444BC807D76DQ37860335-EFC32622-3943-4D95-A920-FD316510DA34Q38212854-BB753DCA-1138-4C89-83B7-56DFBC7C55E8Q38223014-385A380F-349E-48F8-9ADE-1EA9757DBC85Q38260066-2DC4DD41-770B-4558-A4F7-B1C33E1D8D19Q38587368-6C6277D2-8EA1-4011-BE29-7535A0603E3AQ38843215-37EB2683-B13A-430D-A2D6-04A05B6BAF60Q38915914-BC03E876-C9FC-4E30-834C-6605F2B5A08DQ39169967-2DBFB987-1EFE-4C4F-934F-19B05E5BF2EEQ39540759-785ADC13-FA4C-472F-BF55-5FC83759FF3AQ40447961-B8609AFE-3ECE-4F24-816D-8D7975B24A05Q40526825-48BA8F4D-89D6-4BCB-9BE4-373A17CB03A5Q40841438-4476686D-69CE-46EB-A88E-A59B64DFCE17Q41534943-1E7E59DD-6BFE-4052-ADAF-1201C749EDADQ41879018-779EFC03-F537-4333-A63C-3D649B9487F3Q42186848-6707751E-83C7-421C-9983-4C2495BD01B9Q50551450-EC120258-F93D-4935-805B-7DD65FF96747Q52579081-E1E0ED61-FD2B-4AEC-A97C-B5B65A4F9FABQ56531878-E90E6AEC-BD0B-45C1-8559-0FC8443075A4Q56786207-54682112-F87C-4EA2-A14C-9BB7C1BA4ED6Q57269187-632776EE-8070-466B-B0C4-8C462DCB52E4Q57269193-61AE9E9F-68A8-4D75-B9D1-C80820845127Q58293116-6CD7FDEA-3E4C-4FBD-9725-B7116FBA5FAF
P2860
Design strategies of novel NNRTIs to overcome drug resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design strategies of novel NNRTIs to overcome drug resistance.
@en
Design strategies of novel NNRTIs to overcome drug resistance.
@nl
type
label
Design strategies of novel NNRTIs to overcome drug resistance.
@en
Design strategies of novel NNRTIs to overcome drug resistance.
@nl
prefLabel
Design strategies of novel NNRTIs to overcome drug resistance.
@en
Design strategies of novel NNRTIs to overcome drug resistance.
@nl
P50
P1476
Design strategies of novel NNRTIs to overcome drug resistance.
@en
P2093
P304
P356
10.2174/092986709789178019
P577
2009-01-01T00:00:00Z